Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or s… Read more
Genelux Corporation Common Stock (GNLX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.354x
Based on the latest financial reports, Genelux Corporation Common Stock (GNLX) has a cash flow conversion efficiency ratio of -0.354x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.58 Million) by net assets ($18.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genelux Corporation Common Stock - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Genelux Corporation Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Genelux Corporation Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genelux Corporation Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oxford Bank Corporation
PINK:OXBC
|
-0.028x |
|
Biomea Fusion Inc
NASDAQ:BMEA
|
-0.780x |
|
Horizon Minerals Ltd
AU:HRZ
|
-0.107x |
|
Bursa De Valori Bucuresti SA
RO:BVB
|
0.021x |
|
Licogi 16 JSC
VN:LCG
|
N/A |
|
Synergy Innovation Co. Ltd
KQ:048870
|
0.039x |
|
Jinzhou Port Co Ltd A
SHG:600190
|
-22.872x |
|
Blackfinch Spring VCT PLC
LSE:BFSP
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Genelux Corporation Common Stock (2019–2024)
The table below shows the annual cash flow conversion efficiency of Genelux Corporation Common Stock from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $26.27 Million | $-21.23 Million | -0.808x | +22.40% |
| 2023-12-31 | $19.47 Million | $-20.27 Million | -1.041x | -1143.31% |
| 2022-12-31 | $-35.78 Million | $-3.57 Million | 0.100x | -49.82% |
| 2021-12-31 | $-33.11 Million | $-6.58 Million | 0.199x | -37.47% |
| 2020-12-31 | $-22.66 Million | $-7.21 Million | 0.318x | +9.24% |
| 2019-12-31 | $-24.81 Million | $-7.22 Million | 0.291x | -- |